Why is "Androgen deprivation therapy" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-05-03 14:50:20
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Androgen_deprivation_therapy entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-05-03 and was most recently seen on 2026-05-03.
Wikipedia Overview
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent the prostate cancer cells from growing. The pharmaceutical approaches include antiandrogens and chemical castration.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy - Targeted Oncology
-
Determining the Optimal Duration of Androgen-Deprivation Therapy Added to Definitive Radiotherapy in Localized Prostate Cancer - The ASCO Post
-
Navigating Progression After Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer - Cancer Therapy Advisor
-
TXNIP upregulation controls metabolism and cell cycle during androgen deprivation therapy in prostate cancer - Nature
-
ASTRO 2025: Quantifying the Benefits of Adding Androgen Deprivation Therapy versus Dose-Escalation for Prostate Cancer - UroToday
-
A Shot in the Dark: Unprecedented Complete Radiologic Response of Metastatic Prostate Cancer to Single-Dose Androgen Deprivation Therapy (ADT) - Cureus
-
Many men may not need long-term hormone therapy for prostate cancer, study suggests - Medical Xpress
-
TAM Plasticity under androgen deprivation therapy and PARP inhibition in prostate cancer: a multi-omics perspective - Frontiers
-
Nature Communications Publishes Desai Sethi Discovery That Could Transform Prostate Cancer Treatment - University of Miami
-
Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery - News-Medical
-
Mon Health Cancer Center now offers new targeted treatment for advanced prostate cancer - Mon Health
-
Research on prostate cancer disparities and a “buzzy” study - Cedars-Sinai
-
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study - Nature
-
Oral vs Injectable Agents for Androgen-Deprivation Therapy in Prostate Cancer - The ASCO Post
-
Self-help cognitive behavioural therapy for hot flushes and night sweats during androgen deprivation therapy for prostate cancer: the MANCAN2 randomized controlled trial - Nature
-
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer - The ASCO Post
-
Indirect treatment comparisons of darolutamide plus docetaxel and androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer - Nature
-
Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer - Nature
-
Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer - Nature
-
Risk of Alzheimer’s disease and Parkinson’s disease following androgen deprivation therapy in a real world nationwide cohort - Nature
-
Short-Term ADT Plus RT Boosts Prostate Cancer Disease-Free Survival - Physician's Weekly
-
Influence of androgen deprivation therapy on physical performance and muscle strength in prostate cancer patients — a systematic review | Szarzyńska | Reports of Practical Oncology and Radiotherapy - Via Medica Journals
-
City of Hope opens clinical trial to protect heart health of prostate cancer patients receiving hormone therapy - EurekAlert!
-
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer - The ASCO Post
-
5 Side Effects of Androgen Deprivation Therapy for Prostate Cancer — and How to Manage Them - Everyday Health
-
Randomized trial finds drug therapy reduces hot flashes during prostate cancer treatment - EurekAlert!
-
Beyond Hormones Innovative Strategies to Combat Prostate Cancer - Johns Hopkins Medicine
-
Study: Shorter course of ADT may be sufficient for many patients with prostate cancer - Urology Times
-
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data - Nature
-
Enzalutamide Plus Androgen-Deprivation Therapy Shows Durable Survival Benefit for Patients With Metastatic Hormone-Sensitive Prostate Cancer - HMP Global Learning Network
-
UIC researchers awarded $1.2M grant for prostate cancer research - UIC today
-
Androgen Deprivation Therapy–Induced Muscle Loss and Fat Gain Predict Cardiovascular Events in Prostate Cancer Patients - Wiley Online Library
-
Leuprolide Tied to More Coronary Plaque in Prostate Cancer Progression - EMJ
-
ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) - OncLive
-
The Current Landscape of ADT in Prostate Cancer - Urology Times
-
Insulin resistance during androgen deprivation therapy in men with prostate cancer - Wiley
-
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses - American Heart Association Journals
-
Brachytherapy Boost May Decrease the Duration of Androgen-Deprivation Therapy for High-Risk Prostate Cancer - The ASCO Post
-
Testosterone Recovery After Androgen-Deprivation Therapy Linked to Improved Survival in High-Risk Prostate Cancer - The ASCO Post
-
Andrew J. Armstrong, MD, MS, on ARCHES: 5-Year Overall Survival Follow-up - The ASCO Post
-
Addressing Complications from ADT Therapy to Treat Prostate Cancer - Cure Today
-
Androgen Deprivation Therapy for Prostate Cancer - Cure Today
-
Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration - Science | AAAS
-
Overview on Androgen Deprivation Therapy in Prostate Cancer - CancerNetwork
-
Enzalutamide Helps Extend Life for Men with Advanced Prostate Cancer - Duke Health
-
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial - The Lancet
-
Recap: Updates of Androgen Deprivation Therapy in Prostate Cancer - CancerNetwork
-
Testosterone Recovery Uncertain after Androgen Deprivation Therapy for Prostate Cancer - Memorial Sloan Kettering Cancer Center
-
A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer - Wiley
-
New analysis finds timing androgen-deprivation therapy with radiation therapy improves outcomes in localized prostate cancer - UCLA Health
-
Prostate Radiation/Androgen Deprivation Therapy Cost Effective in Prostate Cancer - CancerNetwork
-
RADICALS-HD Trial: Duration of Androgen-Deprivation Therapy With Radiotherapy After Radical Prostatectomy - The ASCO Post
-
Sequencing of androgen-deprivation therapy with radiotherapy for non-metastatic prostate cancer - 2 Minute Medicine
-
Sexual Healing in Patients with Prostate Cancer on Hormone Therapy - ASCO Publications
-
Androgen Deprivation Therapy for Recurrent Prostate Cancer - National Cancer Institute (.gov)
-
Lower Testosterone Threshold May Benefit ADT Recipients - Renal and Urology News
-
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review - Cureus
-
Relugolix Approval Expected to Alter Treatment for Advanced Prostate Cancer - National Cancer Institute (.gov)
-
Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea | Scientific Reports - Nature
-
Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer - Nature
-
The NCCN Guidelines on Androgen Deprivation Therapy in Localized Disease, Regional Disease, and Palliative Treatment - Christopher Wallis and Zachary Klaassen - UroToday
-
Complications of Androgen Deprivation Therapy for Prostate Cancer - Charles Ryan - UroToday
-
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial - The Lancet
-
VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer - 2 Minute Medicine
-
Darolutamide with chemotherapy and androgen-deprivation therapy improves overall survival in metastatic hormone-sensitive prostate cancer - 2 Minute Medicine
-
Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer - Nature
-
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer - Nature
-
Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis | British Journal of Cancer - Nature
-
STAMPEDE: In Nonmetastatic Castration-Sensitive Prostate Cancer, Abiraterone Added to Androgen-Deprivation Therapy Improves Survival - The ASCO Post
-
Changes in the gut microbial profile during long-term androgen deprivation therapy for prostate cancer - Nature
-
Radiation Facility Volume and Survival in Very High–Risk Prostate Cancer Treated With Curative Radiation and Androgen-Deprivation Therapy - The ASCO Post
-
Sexual function in men undergoing androgen deprivation therapy - Nature
-
FSH Is Responsible for Androgen Deprivation Therapy–Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion - American Heart Association Journals
-
Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer - OncLive
-
Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings - Wiley
-
Psychological side effects for common prostate cancer treatment raise concerns - Australian Broadcasting Corporation
-
Apalutamide plus Androgen Deprivation Therapy in Clinical Subgroups of Patients with Metastatic Castration-Sensitive Prostate Cancer: A Subgroup Analysis of the Randomised Clinical TITAN Study - Beyond the Abstract - UroToday
-
Long-course therapy with ADT plus radiotherapy after surgery improves MFS in prostate cancer - Urology Times
-
Depression, Anxiety Rates High With Androgen Deprivation Therapy for Prostate Cancer - Oncology Nurse Advisor
-
Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer - Nature
-
Gut environment changes due to androgen deprivation therapy in patients with prostate cancer - Nature
-
Kolenko Receives Grant to Study Link Between Cholesterol and Androgen Deprivation Therapy Resistance in Prostate Cancer - Fox Chase Cancer Center
-
Dry Eye Can Develop With Androgen Deprivation Therapy - Ophthalmology Advisor
-
Adding Docetaxel to Androgen-Deprivation Therapy Prolongs Overall Survival in Metastatic Prostate Cancer - The ASCO Post
-
The ARANOTE Phase 3 Trial of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume - OncLive
-
The Androgen Deprivation Therapy Landscape in 2024 – Co-navigating the Available Options with Prostate Cancer Patients - EMJ
-
Discussion Optimizing the Use of Androgen Deprivation Therapy in Men with Intermediate-Risk Prostate Cancer - Michael Cookson, Alicia Morgans & Felix Feng - UroToday
-
Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system - Nature
-
Quality of Life Study in Early Prostate Cancer Shows Neoadjuvant Androgen Deprivation Therapy May Not Improve Quality of Life - Cleveland Clinic
-
Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy - Nature
-
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapy - Nature
-
Androgen-Deprivation Therapy Added to Radiation Therapy Improves Disease Control in Intermediate-Risk Prostate Cancer - The ASCO Post
-
Assessing Cardiovascular Risk of Men with Prostate Cancer on Androgen Deprivation Therapy - Michael Cookson, Alicia Morgans, Bertrand Tombal & Javid Moslehi - UroToday
-
Statin Use at Start of Androgen-Deprivation Therapy Increases Time to Progression During Treatment of Prostate Cancer - The ASCO Post
-
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial - Fred Saad - UroToday
-
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study - Nature
-
Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study | British Journal of Cancer - Nature
-
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial - Nature
-
Inflammation from Androgen Deprivation Therapy May Cause Fatigue in Prostate Cancer Patients - Moffitt
-
PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression - Nature
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.